Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2009 (2009), Article ID 135143, 5 pages
Clinical Study

Management for Patients with De Novo or Recurrent Tumors in the Residual Kidney after Surgery for Nonfamilial Bilateral Renal Cell Carcinoma

1Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan
2Division of Radiation Oncology, Department of Molecular Genetics, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan
3Division of Radiology, Mie University Graduate School of Medicine, Mie 514-8507, Japan
4Department of Urology, Niigata Cancer Center Hospital, Niigata 951-8566, Japan

Received 25 June 2009; Accepted 16 September 2009

Academic Editor: Michael P. Porter

Copyright © 2009 Noboru Hara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The tumor de novo in the residual kidney after surgery for nonfamilial bilateral renal cell carcinoma (RCC) is problematic. We reviewed 5 patients who experienced such a situation. Three patients had had metachronous bilateral RCC, treated with radical nephrectomy in one kidney and nephron-sparing surgery (NSS) in the other. Two patients had had synchronous disease; one patient had received radical nephrectomy and NSS, and the other bilateral NSS. The 5 patients had another solid mass/de novo tumor in the residual kidney 16–88 (mean 46.8) months after surgery. For the tumor de novo in earlier years (1992–1999), one patient underwent surgery and hemodialysis, and the other selected a conservative observation. In recent years (2000–2007), one patient was conservatively observed; the remaining 2 received computerized-tomography-guided radiofrequency ablation, and the local tumors were well controlled postoperatively for 20 and 12 months with their renal function unimpaired. Ablative techniques can potentially strike a balance between oncological and nephrological outcomes in patients with sporadic multiple RCC, successful management of which was difficult previously.